<scp>CD34</scp>+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (<scp>EBMT</scp>)
Enrico Maffini(Istituto di Ematologia di Bologna), Mohamad Mohty(Sorbonne Université), Didier Blaise(Institut Paoli-Calmettes), Francesco Lanza(Ospedale "Santa Maria delle Croci" di Ravenna), Fabio Ciceri(Vita-Salute San Raffaele University), P. Chevallier(Centre Hospitalier Universitaire de Nice), Myriam Labopin(Sorbonne Université), Norbert Claude Gorin(Sorbonne Université), Zafer Gülbaş, Arnon Nagler(Sheba Medical Center), Mercedes Colorado Araujo(Marqués de Valdecilla University Hospital), Yener Koç(Antalya IVF), Bipin N. Savani(Vanderbilt University Medical Center), Gèrard Socié(Hôpital Saint-Louis), Véronique Leblond(Sorbonne Université), Éric Deconinck(European Union)
Cited by 39
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k